The short shelf life of platelet concentrates (PC) of up to 5–7 days leads to higher wastage due to expiry. To address this massive financial burden on the healthcare system, alternative applications for expired PC have emerged in recent years. Engineered nanocarriers functionalized with platelet membranes have shown excellent targeting abilities for tumor cells owing to their platelet membrane proteins. Nevertheless, synthetic drug delivery strategies have significant drawbacks that platelet-derived extracellular vesicles (pEV) can overcome. We investigated, for the first time, the use of pEV as a carrier of the anti-breast cancer drug paclitaxel, considering it as an appealing alternative to improve the therapeutic potential of expired PC. The pEV released during PC storage showed a typical EV size distribution profile (100–300 nm) with a cup-shaped morphology. Paclitaxel-loaded pEV showed significant anti-cancer effects in vitro, as demonstrated by their anti-migratory (>30%), anti-angiogenic (>30%), and anti-invasive (>70%) properties in distinct cells found in the breast tumor microenvironment. We provide evidence for a novel application for expired PC by suggesting that the field of tumor treatment research may be broadened by the use of natural carriers.
Human induced pluripotent stem cells (hiPSC) have great potential for cell therapy applications. To meet the global demand for hiPSC‐derived cell therapies, the implementation of scalable technologies, such as stirred‐tank bioreactors (STB), is essential. However, the addition of physical cues, including shear stress, can impact cell viability and proliferation and requires precise tuning. In this work, we used an engineering characterization approach to estimate the impeller power number (0.5) and investigate the mixing and suspension dynamics in the first generation of small‐scale (0.2 L) DASGIP bioreactors (DASGIP‐STB). By keeping constant power input per volume (P/V = 4.6 W/m3) as a scale‐up criteria, we successfully transferred a hiPSC expansion process to a 0.2 L single‐use STB (BioBLU‐STB) and scaled it up to a single‐use 2 L STB (Univessel‐STB) without compromising cell expansion, viability, and metabolism, as well as hiPSC quality attributes, including their pluripotent phenotype and differentiation potential.